HPN-217 is under clinical development by Harpoon Therapeutics and currently in Phase II for Relapsed Multiple Myeloma. According to GlobalData, Phase II drugs for Relapsed Multiple Myeloma have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how HPN-217’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
HPN-217 is under development for the treatment of relapsed and refractory multiple myeloma. The drug candidate is a tri-specific antibody and T cell engager. It has three binding domains, one arm bind to cancer cells, second arm to capture and engage bypassing T cells and third arm bind to human serum albumin. It acts by targeting B cell maturation antigen (BCMA) and CD3. It is developed based on tri-specific T-cell Activating Construct (TriTAC) platform. It is administered through intravenous route.
It was also under development for mantle cell lymphoma.
Harpoon Therapeutics overview
Harpoon Therapeutics (Harpoon) is a clinical-stage immuno-oncology company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. The company’s pipeline products include Hpn424, a T cell-engaging bispecific antibody used for the treatment of prostate cancer; HPN536 against ovarian cancer; HPN217 targeting Multiple Myeloma; HPN328 indicated for small cell lung cancer; and HPN601, is a protease-activated EpCAM targeting T cell engager for the treatment of solid tumors. It utilizes Tri-specific T cell activating construct (TriTAC) platform, for developing a pipeline of novel T cell engagers designed for targeted penetration and destruction of solid tumors and hematologic malignancies. Harpoon is headquartered in South San Francisco, California, the US.
For a complete picture of HPN-217’s drug-specific PTSR and LoA scores, buy the report here.